南京医科大学学报（自然科学版）2024，Vol.44Issue(4)：524-535,572,13.DOI:10.7655/NYDXBNS20231154
葡萄糖代谢重编程在胰腺癌耐药中的研究进展
Research progress of glucose metabolic reprogramming in drug resistance of pancreatic cancer
摘要
Abstract
Pancreatic cancer is a highly lethal and aggressive tumor that affects the digestive tract,leading to poor prognosis and low survival rate.At present,gemcitabine-based chemotherapy is widely used in the clinical treatment of pancreatic cancer.However,the efficacy of chemotherapy has significantly decreased with the emergence of clinical drug resistance.In order to meet its demand of energy and biological materials,tumors always change its metabolic pathway,which is called tumor metabolic reprogramming.The abnormal enhancement of aerobic glycolysis is one of characteristics of glucose metabolic reprogramming in pancreatic cancer cells.The glucose transporter proteins and key enzymes are participated in the processes and regulated chemotherapy resistance through different signal pathways.The purpose of this study is to summarize the relationship between drug resistance and glucose metabolic reprogramming in pancreatic cancer.The mechanisms and regulatory signaling pathways are also analyzed.Furthermore,the pre-clinical trials and drug development targeting the glycolysis metabolic pathways are summarized and analyzed.关键词
胰腺癌/葡萄糖代谢重编程/有氧糖酵解/化疗耐药Key words
pancreatic cancer/glucose metabolic reprogramming/aerobic glycolysis/chemotherapy resistance分类
医药卫生引用本文复制引用
喻悦,王瑜亮,张晓..葡萄糖代谢重编程在胰腺癌耐药中的研究进展[J].南京医科大学学报（自然科学版）,2024,44(4):524-535,572,13.基金项目
国家自然科学基金(81872426) （81872426）
